Jupiter Neurosciences, Inc. JUNS 深 滬
交易中 09-25 10:15:16 美东时间
2.885
0.000
0.00%
華盛通- 最 高2.82
- 今 開2.82
- 成交量 2310股
- 最 低 2.82
- 昨 收 2.885
- 總市值 380.39万
- 52周最高 135.75
- 市盈率 靜 --
- 換手率 0.18%
- 52周最低 2.80
- 委 比 89.75%
- 總股本 131.85万
- 歷史最高 1463.25
- 量 比 0.33
- 振 幅 0.00%
- 歷史最低 2.82
- 每 手 1
- 風險率 38.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Webuy Global Ltd (NASDAQ:WBUY) rose sharply in pre-market trading. Webuy reported record preliminary unaudited travel bookings of around $4.76 million during the three-day NATAS Fair in Aug. 2026, representing around 42% surge from the more than US$3.34 million figure announced during the ...
08-31 16:53
Jupiter Neurosciences Faces Nasdaq Delisting Risk Despite Compliance
Jupiter Neurosciences, Inc. ( ($JUNS) ) has issued an update. On August 27, 202...
08-29 04:58
Jupiter Neurosciences Gains Relief from Insider Debt Forgiveness
Jupiter Neurosciences, Inc. ( ($JUNS) ) has shared an update. On August 26, 202...
08-27 18:58
Jupiter Neurosciences announces pricing of $2M registered direct offering
Jupiter Neurosciences (JUNS) on Friday said it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. Shares of t...
08-22 02:01
Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?
Jupiter Neurosciences stock was up 43.52% on Friday after the company announced...
08-22 01:01
Jupiter Neurosciences Commences ~$2M Offering Of 307,692 Common Shares
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of com...
08-22 00:22
Jupiter Neurosciences Enters Definitive License Agreement With PharmAla For Its Patented, Non-Racemic MDMA Formulation ALA-002
Two developments have since materially changed the context for that structure. First, on July 20, 2026, PharmAla executed a definitive license agreement granting Jupiter Neurosciences, Inc. (NASDAQ:JUNS) exclusive U.S. rights to ALA-002, demonstrating that PharmAla is able to monetize its assets dir...
08-21 19:08
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences, Inc. has entered into a securities purchase agreement to sell 307,692 shares of common stock in a registered direct offering, raising approximately $2.0 million. D. Boral Capital LLC is acting as the exclusive placement agent, with the offering expected to close on August 24, 2026. The shares are being offered under an effective shelf registration statement on Form S-3, and a prospectus supplement will be filed with the SEC...
08-21 16:20
Jupiter Neurosciences announces 1-for-75 reverse stock split
Jupiter Neurosciences (NASDAQ: JUNS) said on Wednesday it has approved a 1-for-75 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split will take effect after...
08-05 20:53
Jupiter Neurosciences Announces 1-For-75 Reverse Stock Split, Effective Aug. 6
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and neurodegenerative disorders, today announced that the board of directors of the Company approved a 1-for-75 reverse stoc...
08-05 20:03
